journal article·2018-06-13

Photoresponsive Nanovehicle for Two Independent Wavelength Light-Triggered Sequential Release of P-gp shRNA and Doxorubicin To Optimize and Enhance Synergistic Therapy of Multidrug-Resistant Cancer

Ming Wu, Xinyi Lin, Xionghong Tan, Jiong Li, Zuwu Wei, Da Zhang, Youshi Zheng, Ai-xian Zheng, Bixing Zhao, Yongyi Zeng, Xiaolong Liu, Jingfeng Liu

ACS Applied Materials & Interfaces· Volume 10· Issue 23
Publisher page

Abstract

Prerelease of RNA molecules than chemotherapeutic drugs with a sufficient interval is a vital prerequisite for RNA/drug co-delivery strategy to overcome multidrug resistance (MDR) of cancer cells, but how to precisely control their release at different time points is still a grand challenge up to now. This study aims to on-demand remotely manipulate RNA and drug release in real time through single delivery system to sequentially play their respective roles for optimizing and enhancing their synergistic antitumor effects. To this end, a photoresponsive mesoporous silica nanoparticle (PMSN) is fabricated as a co-delivery vehicle of P-glycoprotein (P-gp) short-hairpin RNA (shRNA) and photocaged prodrug of doxorubicin (DOX), by which the orthogonal and sequential release of shRNA and DOX can be achieved using an external light. In our design, the cationic poly[2-( N, N-dimethylaminoethyl)methacrylate] is introduced onto the PMSN surface through a light-sensitive coumarin ester derivative linker to adsorb P-gp shRNA, whereas the photocleavable o-nitrobenzyl ester derivative-caged DOX is loaded into the inner pores of the PMSN. The PMSN is found to be effectively internalized by MDR cancer cells, and the release of the shRNA and DOX is demonstrated to be independently regulated by 405 and 365 nm light irradiations due to selectively cleaved coumarin and o-nitrobenzyl ester, resulting in enhanced drug retention, and finally bring out optimized and significantly improved chemotherapeutic effects both in vitro and in vivo for MDR cancer treatment, which might hold extensive application prospects in MDR cancer treatment in future.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced biosensing and bioanalysis techniques · RNA Interference and Gene Delivery · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, P. R. China

The Liver Center of Fujian Province, Fujian Medical University, Fuzhou 350025, P. R. China

School of Life Sciences, Fujian Agriculture and Forestry University, Fuzhou 350002, P. R. China

Liver Disease Center, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, P. R. China

Funding

Natural Science Foundation of Fujian Province · National Natural Science Foundation of China · Scientific Foundation of Fuzhou City · Health and Family Planning Commission of Fujian Province · Fujian Province · Health and Education Commission of Fujian Province

References (44)

Show source-provided references
1. 10.1016/j.biomaterials.2014.06.03510.1016/j.biomaterials.2014.06.035 ↗
2. 10.1002/smll.20130395110.1002/smll.201303951 ↗
3. 10.1093/jnci/92.16.129510.1093/jnci/92.16.1295 ↗
4. 10.1002/path.170610.1002/path.1706 ↗
5. 10.1002/biot.20110005410.1002/biot.201100054 ↗
6. 10.1016/j.jconrel.2007.07.01610.1016/j.jconrel.2007.07.016 ↗
7. 10.1021/nn401079610.1021/nn4010796 ↗
8. 10.1021/jacs.6b0411510.1021/jacs.6b04115 ↗
9. 10.1002/anie.20131058910.1002/anie.201310589 ↗
10. 10.1021/acs.macromol.6b0137410.1021/acs.macromol.6b01374 ↗
11. 10.1021/acs.macromol.6b0216210.1021/acs.macromol.6b02162 ↗
12. 10.1021/nn201370710.1021/nn2013707 ↗
13. 10.1016/j.jconrel.2014.10.01810.1016/j.jconrel.2014.10.018 ↗
14. 10.1021/nn100690m10.1021/nn100690m ↗
15. 10.1002/smll.20090062110.1002/smll.200900621 ↗
16. 10.1002/smll.20100152210.1002/smll.201001522 ↗
17. 10.1016/j.biomaterials.2012.10.02410.1016/j.biomaterials.2012.10.024 ↗
18. 10.1021/ja900591t10.1021/ja900591t ↗
19. 10.1021/ja103415t10.1021/ja103415t ↗
20. 10.1039/c1cs15023e10.1039/c1cs15023e ↗
21. 10.1021/ja052101910.1021/ja0521019 ↗
22. 10.1021/ja991014b10.1021/ja991014b ↗
23. 10.1016/S0165-0270(01)00451-410.1016/S0165-0270(01)00451-4 ↗
24. 10.1002/cbic.20160001910.1002/cbic.201600019 ↗
25. 10.1021/la802052u10.1021/la802052u ↗
26. 10.1021/ja907287n10.1021/ja907287n ↗
27. 10.1021/ja110572j10.1021/ja110572j ↗
28. 10.1002/anie.20130817410.1002/anie.201308174 ↗
29. 10.1016/j.actbio.2014.09.00410.1016/j.actbio.2014.09.004 ↗
30. 10.1021/nn404698510.1021/nn4046985 ↗
31. 10.1002/adfm.20080112710.1002/adfm.200801127 ↗
32. 10.1021/am401059k10.1021/am401059k ↗
33. 10.1039/C3TB21015D10.1039/C3TB21015D ↗
34. 10.1016/S0926-2040(02)00018-810.1016/S0926-2040(02)00018-8 ↗
35. 10.1021/ma801546z10.1021/ma801546z ↗
36. 10.1002/smll.20150276010.1002/smll.201502760 ↗
37. 10.1039/C5NR09112H10.1039/C5NR09112H ↗
38. 10.1021/acsnano.7b0031210.1021/acsnano.7b00312 ↗
39. 10.1016/S0169-409X(02)00046-710.1016/S0169-409X(02)00046-7 ↗
40. 10.1002/adfm.20130213310.1002/adfm.201302133 ↗
41. 10.1002/anie.20090025510.1002/anie.200900255 ↗
42. 10.1039/C4RA16138F10.1039/C4RA16138F ↗
43. 10.1002/advs.20160046010.1002/advs.201600460 ↗
44. 10.1002/advs.20170064810.1002/advs.201700648 ↗